Summary Tumour cell adhesion, detachment and aggregation seem to play an important part in tumour invasion and metastasis, and numerous cell adhesion molecules are expressed by tumour cells. Several families of cell-cell adhesion molecules have been described, of which two groups are particularly well characterised, the cadherin family and the Ig superfamily member, neural cell adhesion molecule (NCAM). We investigated expression of these two adhesion molecule families in small cell lung cancer (SCLC) Small cell lung cancer (SCLC) is a common human malignancy with an aggressive behaviour and a high tendency to metastasize. Tumour cell adhesion, detachment and aggregation seem to play an important part in tumour invasion and metastasis, and cell adhesion molecules are frequently expressed by tumour cells (Nicolson, 1988; Thiery et al., 1988; Linnemann et al., 1989; Shimoyama et al., 1989) . Cell-cell adhesion molecules may be classified into several groups (Takeichi, 1991; Bock, 1991; of which the cadherin family constitutes one important group, and the Ig superfamily member, neural cell adhesion molecule (NCAM) another. Both these families of adhesion molecules have been attributed a role in embryonic development and both are expressed in certain forms of cancer as well as in several normal adult tissues (Thiery et al., 1988) .
Cadherins are a family of cell adhesion molecules of which several subclasses are well characterised. Four major subclasses are termed N-cadherin (Mr 127-135.000), E-cadherin (Mr 124.000) (also designated uvomorulin), P-cadherin (Mr 118.000), and L-CAM (Mr 124.000) (Takeichi, 1991) . The cadherin family members are differentially expressed during morphogenesis, and may play a role in tumour invasion and metastasis, but the functional differences between the members have not been clarified.
At present, only little is known about cadherin expression in SCLC (Shimoyama et al., 1989) .
NCAM is widely expressed during embryonic development as well as in adult neural and several other tissues and in certain tumours (Schol et al., 1988; Thiery et al., 1988) . It exists in several different isoforms varying in their Mr, mainly due to differences in length of the C-terminal end of the molecule (for reviews, see Nybroe, Linnemann & Bock, 1988; . All isoforms are encoded by the same gene due to alternative mRNA splicing (Owens, Edelman & Cunningham, 1987; Santoni et al., 1989) . Three isoforms with Mr's of approximately 190, 135 and 115 kD are most commonly expressed, and are therefore termed major isoforms. The specific functional role played by each of these isoforms is not known.
A characteristic of NCAM is that it may contain various amounts of a2,8-linked polysialic acid (PSA) side chains (Finne, 1982) , which may profoundly alter its homophilic binding abilities (Hoffman & Edelman, 1983; Rutishauser et al., 1988) , and thereby possibly the invasive and metastatic capacity of the cells expressing NCAM. NCAM expression has been reported to be present in almost all cases of SCLC (Souhami et al., 1991; Kibbelaar et al., 1989; Aletsee-Ufrecht et al., 1990) . Most previous studies of NCAM expression in SCLC have utilised immunohistochemical investigation. This method gives information about the subcellular localisation of NCAM, but it does not enable distinction between the different isoforms, neither does it provide detailed information about NCAM polysialylation, although demonstration of polysialylation is possible with appropriate antibodies (Kibbelaar et al., 1989; Souhami et al., 1991) .
In (Pettengill et al., 1980) , the NCI tumour at the National Cancer Institute, MD, USA (Carney et al., 1985) , and GLC tumours at University Hospital of Groningen, The Netherlands (de Leij et al., 1985; Berendsen et al., 1988) . CPH-54A and CPH-54B are in vitro established subclones of the same original tumour (Engelholm et al., 1985) . were established from the same patient during longitudinal follow-up (Berendsen et al., 1988 (Moolenaar et al., 1990) ; the specificity of this antibody has been described previously (Rasmussen et al., 1983) . Following incubation with primary antibody, the membranes were washed and incubated for 1 h with alkaline phosphataseconjuated swine anti-rabbit antibody (Dakopatts, Glostrup, Denmark) diluted 1:1000. After washing, bound antibody was visualised by a chromogenic reaction catalysed by the conjugated alkaline phosphatase using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as the chromogenic substrate.
Results
The results are summarised in Table I (Shimoyama et al., 1989) , of which 2/2 SCLC cell lines were found to be positive.
In ten of the 18 cadherin expressing tumours the Western Table I and text. Figure 1) . Cadherin antibodies binding to the C-terminal part of cadherin, as does the antibody used in this study, has been reported to recognise both E-, N-, and P-cadherin (Geiger et al., 1990) . N-cadherin is the largest of the known cadherins, and thus the larger band found in all cadherin expressing tumours is very likely to be N-cadherin. This assumption is favoured by the fact that the large band always co-migrated closely with the N-cadherin band in rat brain tissue. The smaller band found in ten of the tumours may represent one of the other described cadherin family members, a breakdown product of N-cadherin, or yet unidentified members of the cadherin family. With the increasing knowledge about the complexity of the cadherin family, it is evident that some caution must be exercised when interpreting results obtained with antibodies with broad cadherin family reactivity. Four cadherin subclasses have been well characterised, namely E-, N-, P-cadherin and L-CAM (Takeichi, 1991) but several more may exist (Suzuki, Sano & Tanihara, 1991) .
NCAM was expressed in 18/19 of the tumours. This is in agreement with previous reports of very frequent expression of NCAM in SCLC (Schol et al., 1988; Kibbelaar et al., 1989; Aletsee-Ufrecht et al., 1990) .
While NCAM has for some time been known to be expressed in SCLC, little was known about which isoforms of NCAM that were expressed in this disease (Souhami et al., 1991) . This is due to the fact that the majority of previous studies have employed immunohistochemical methods for demonstration of NCAM; such methods do not allow distinction between the various NCAM isoforms. In one study of NCAM expression in seven SCLC cell lines by immunoblotting (Aletsee-Ufrecht et al., 1990) , only the NCAM-135 isoform was demonstrated (termed NCAM 140 in their study). In two other previous studies in which SCLC NCI-H69 was included (Kibbelaar et al., 1989; Moolenaar et al., 1990) , this tumour was shown to express both . The expression of these two major isoforms in NCI-H69 was confirmed in the present study. We found coexpression of NCAM-190 and NCAM-135 in more than half of the examined tumours, demonstrating that, in SCLC, two NCAM isoforms are commonly co-expressed. Since the role of the different NCAM isoforms is not settled, the possible biological implications of the difference in NCAM isoform expression between various SCLC tumours remains obscure.
It has recently been demonstrated, that the antigen recognised by SCLC cluster one (Cl 1) antibodies (Souhami et al., 1991) is identical to NCAM (Patel et al., 1989; Moolenaar et al., 1990) . Most SCLC tumours investigated so far have been found to express NCAM, while expression is found in only a few non-SCLC lung tumours (Mooi et al., 1988; Kibbelaar et al., 1989; Aletsee-Ufrecht et al., 1990) .
We detected polysialylation in 14/18 tumours (Table I) , but we cannot rule out the possibility that a lower level of polysialylation may be present in the tumours scored as negative. Low levels of polysialylation may be detectable with antibodies with high affinity for a2,8-linked polysialic acid side chains. Polysialylation of NCAM profoundly reduces the homophilic binding properties of cells (Rutishauser et al., 1988) and may facilitate migration of the cells due to altered cell-cell interactions. Thus, it could be speculated that the presence of polysialylation of NCAM on SCLC cells may contribute to the highly metastatic behaviour of this tumour type.
Qualitatively, the expression pattern of cadherin and NCAM was independent of whether the individual tumours were grown in vitro as cell lines or in vivo as nude mouse xenografts. However, a tendency towards higher expression in cell lines than in xenografts was noted. The difference may to some extent be caused by the presence in xenografts of murine stroma, which causes a dilution of the tumour cells. Despite the possible slight difference in the level of cadherin and NCAM expression between cell lines and xenografts, the demonstration of these adhesion molecules both in cell lines and in xenografts is evidence that expression is an inherent characteristics of the SCLC tumour cells, and not a phenotypic feature induced by the growth conditions. This notion is supported by the consistent demonstration of NCAM expression in SCLC in surgical biopsies (Mooi et al., 1988; Kibbelaar et al., 1989; Tome et al., 1990) , as well as in cell lines established from patients with this disease (Kibbelaar et al., 1989; Moolenaar et al., 1990; Aletsee-Ufrecht et al., 1990) .
It has been suggested that NCAM expression may be a feature specific of SCLC cell lines growing as floating aggregates in in vitro culture whereas cells growing adherent to the bottom of culture flasks express less or no NCAM (Doyle et al., 1990) . Our data do not support this hypothesis since the CPH cell lines, the DMS cell lines except DMS-79, and GLC-3 grew attached to the bottom of culture flasks. Thus, 10/14 cell lines expressed NCAM and grew attached.
At least three different types of cell-cell adhesion molecules are expressed on SCLC cells. Apart from cadherin and NCAM, also PI integrin is expressed in a large proportion of SCLC cells (Feldman et al., 1991) . Cell-cell adhesion molecules are likely to be involved in the process of metastasis (Nicolson, 1988; Thiery et al., 1988; Takeichi, 1991) . However, it is not clear what influence adhesion molecules on the surface of cancer cells have on their ability to metastasise. On one hand adhesion molecules may retard the escape of tumour cells from the primary site due to increased adhesion to other cells and to intercellular matrix proteins, but on the other hand adhesion molecules may be necessary for the cells to attach to a secondary, i.e. metastatic, site. However, decreased metastatic potential of cells expressing NCAM was reported (Andersson et al., 1991) and also increased invasive and metastatic potential upon loss of cadherin expression (Behrens et al., 1989; Hashimoto et al., 1989; Vleminckx et al., 1991) has been described. Hence, the functional role of adhesion molecules in invasion and metastasis is complex, and it may seem surprising that SCLC which is highly metastatic in patients, expresses several types of adhesion molecules.
